Drug Profile
Research programme: heat shock protein inhibitors - Pfizer
Alternative Names: PF-3823863; PF-4470296; PF-4942847Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Amides; Isoindoles; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Triple negative breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (PO)
- 31 Mar 2011 Pharmacodynamics data from preclinical trial in Cancer presented at the 241st American Chemical Society National Meeting (241st-ACS-2011)